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The Ebers papyrus, written some 3,500 
years ago in ancient Egypt, advocated 
applying a decoction of dried myrtle 
leaves to the abdomen and back to relieve 
rheumatic pains in the womb. Hippocrates 
advised the juices of the poplar tree to cure 
eye disorders and the juices of willow bark 
to relieve childbirth pain and lower fever a 
thousand years later. Salicylates are 
present in all of these therapeutic 
treatments. 
The use of extracts of salicylate-containing 
plants, particularly the bark of the willow 
tree (Salix alba and other members of the 
Salix species), in the treatment of fever, 
pain, and inflammation, gave rise to anti-
inflammatory analgesic medications. 
Inflammation is the body's natural 
response to harm. Enzyme activation, 
mediator release, fluid extravasation, cell 
migration, tissue disintegration, and repair 
are all part of the process. This paper will 
focus on the aspects of anti-inflammatory 
medicines that are affected, with a 
particular focus on the prostaglandin (PG) 
system. Phospholipase A2 activates this, 
releasing arachidonic acid, the 
cyclooxygenase substrate (COX or 
prostaglandin H2 [PGH2] synthase). 
Prostaglandin production rises as a result 
of this. COX is a dual-function enzyme 
that performs both cyclooxygenase and 
peroxidase functions. 
Following the publishing of what were 
possibly the first clinical trials of willow 
bark extract for the treatment of agues or 
fever by the Reverend Edward Stone in the 
17th century, the popularity of these plant 
extracts grew during the 17th–19th 
centuries. In the early 19th century, the 
main active salicylate components were 
isolated, and in the mid-late 19th century, 
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advances in chemistry in Europe and 
developments in the German chemical 
industry led to the synthesis of salicylic 
and acetylsalicylic acids, the latter of 
which was highly successful 
commercialised by Bayer AG as 
AspirinTM over 100 years ago. 
In inflammatory circumstances ranging 
from experimental acute edema and 
sunburn to chronic arthritis, PGE2 is the 
most common eicosanoid found in 
humans. Because inflammation is one of 
the few settings in which PGE2 is a 
prominent product of COX, it's probable 
that the enzymatic route is directed 
towards this product by the inflammation 
process. A second enzyme, 5-
lipoxygenase, transforms arachidonic acid 
to leukotrienes, which are important 
asthma mediators. (1) PGE2 is a powerful 
dilator of vascular smooth muscle, which 
explains why acute inflammation causes 
vasodilation and erythema (redness). (2) 
Vasodilation increases blood flow through 
inflamed tissues, which exacerbates the 
edema induced by vascular permeability-
increasing substances such bradykinin and 
histamine. (3) Inflammatory pain is also 
caused by PGE2, which works in concert 
with other mediators. PGE2 sensitizes 
receptors on afferent nerve endings to the 
effects of bradykinin and histamine 
without directly causing pain. (4) 
Furthermore, PGE2 is a potent pyretic 
agent, and its production in bacterial and 
viral infections, which is driven by the 
release of interleukin-1 (IL-l), adds to the 
associated fever. (5) 
Inflammatory lesions have been found to 
contain a variety of COX products. PGFm, 
PGD2, prostacyclin (PGI2 as 6-oxo-PGF1 
alpha) and thromboxane A2 (TXA2 [as 
TXB2]) are among them, but their 
concentrations are usually less than a fifth 
of those of PGE2. Prostacyclin, which is 
likewise a powerful vasodilator and a more 
potent hyperalgesic agent than PG2, is 
arguably the most important of these 
compounds in terms of inflammatory 
symptoms. Both PGEz and prostacyclin 
are believed to play a role in the 
development of inflammatory erythema 
and discomfort. (6) 
Discovery of NSAIDs 
Phenylbutazone (by JR Geigy, Basel, 
Switzerland) and later indomethacin (by 
Merck & Co, Rahway, NJ, USA) were the 
earliest of the nonsteroidal anti-
inflammatory medications (NSAIDs), of 
which aspirin is now recognized as the 
progenitor. Initially, phenylbutazone was 
used in conjunction with antipyrine in the 
hopes of enhancing the latter's effects. 
However, it was discovered to have greater 
anti-inflammatory/analgesic activity than 
antipyrine and was successfully used for 
the treatment of arthritic and other painful 
inflammatory conditions for the better part 
of 30 years until its popularity waned after 
associations with life-threatening 
agranulocytosis and bone marrow 
suppression (still largely unproven today), 
upper respiratory infections, and other side 
effects. 
2. Mechanism of Action of Steroids in 
Inflammation 
Anti-inflammatory drugs known as 
corticosteroids are commonly used to treat 
rheumatologic disorders such as 
rheumatoid arthritis, lupus, and vasculitis 
(inflammation of the blood vessels). The 
drugs cortisone and prednisone are 
examples of specific corticosteroids. 
Corticosteroids diminish arachidonic acid 
release via inhibiting the activity of 
phospholipase A2. As a result, 
corticosteroids stop prostaglandins, 
thromboxane, and leukotrienes from 
forming. Anti-inflammatory hormones 
inhibit phospholipase A2 indirectly by 
releasing lipocortin 1, an inhibitory 
protein. (7) 
Inhibiting phospholipase-induced edema in 
the rat paw, recombinant lipocortin 1 
inhibits the release of eicosanoids from 
human tissues (8) and is a strong anti-
inflammatory drug. (9) In reaction to 
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glucocorticoids, not all types of cells make 
lipocortin l. Glucocorticoids are 
corticosteroids that bind to the 
glucocorticoid receptor, which is found in 
nearly every vertebrate animal cell. (10) 
The word "glucocorticoid" alludes to its 
role in glucose metabolism, adrenal cortex 
synthesis, and steroidal structure. 
Glucocorticoids have an effect on cells by 
binding to the glucocorticoid receptor. The 
activated glucocorticoid receptor-
glucocorticoid complex upregulates anti-
inflammatory protein expression in the 
nucleus (transactivation), while repressing 
proinflammatory protein expression in the 
cytosol (trans-repression) by preventing 
other transcription factors from the cytosol 
from entering the nucleus. (11) 
 
Figure 1. Chemical Classification of the NSAIDs 
Another component of glucocorticoids' 
anti-inflammatory effect is their 
suppression of inducible cyclooxygenase-2 
(COX-2) synthesis. They bind to and 
activate cytoplasmic glucocorticoid 
receptors, which regulate the transcription 
of numerous key response genes such as 
COX-2 and nitric oxide synthase. 
3. Mechanism of Action of Non-
Steroidal Anti-Inflammatory Agents 
It's hard to believe, but before 1971, no 
one knew how aspirin, the world's most 
widely used nonprescription medicine, 
worked. Since the active principle of 
willow bark was identified in 1876, the 
pharmacologic effects of aspirin and other 
nonsteroidal anti-inflammatory medicines 
(NSAIDs) have been known. (12) Aspirin 
inhibits COX by causing irreversible 
acetylation of the cyclooxygenase 
component, leaving the enzyme's 
peroxidase activity unchanged (13) 
NSAIDs such as indomethacin and 
ibuprofen, in contrast to aspirin's 
irreversible action, generate reversible 
COX inhibition by competing with the 
enzyme's substrate, arachidonic acid, for 
the active site. (14) 
All of the activities of aspirin-like 
medications can be explained by inhibiting 
prostaglandin production. They inhibit the 
pathological overproduction of 
prostaglandins, which lead to 
inflammation (therapeutic actions) and the 
physiological creation of prostanoids 
(which results in the characteristic side 
effects). Aspirin's ulcerogenic potential 
stems from its reduction of prostacyclin 
synthesis, which is a key cytoprotective 
component of the gastric mucosa. (15) 
Experimental stomach ulcers can be 
reversed or prevented with the 
administration of several prostaglandins 
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(16), and some of the recently produced 
prostaglandin derivatives are now 
available for clinical usage. Furthermore, 
NSAIDs' ability to erode the stomach 
mucosa is linked to their ability to 
suppress COX. 
NSAIDs have been shown to decrease 
prostaglandin synthesis in a range of cell 
types and tissues, ranging from whole 
animals and humans to microsomal 
enzyme preparations. The concentration of 
a PGEz-like molecule in the synovial fluid 
of rheumatoid arthritis patients, for 
example, is around 20 ng/ml. This falls to 
zero in patients on aspirin, providing 
clinical evidence of the drug's influence on 
prostaglandin synthesis. (17) Several 
inhibitor classes have been found (18), 
with at least 12 key chemical series known 




Figure 2. Process involved in production of prostaglandins and leukotrienes 
4. A Second Cyclooxygenase Enzyme 
has Been Found 
Needleman and colleagues discovered 
that bacterial endotoxin significantly 
boosted COX activity in human monocytes 
in vitro (20) and mice peritoneal 
macrophages in vivo. (21, 22) 
Dexamethasone inhibited this rise, which 
was linked to the creation of new COX 
protein. An inducible synthase was 
discovered a year or so later as an unique 
isoform of cyclooxygenase (COX-2) 
encoded by a different gene than the 
constitutive enzyme (COX-1). (23) 
Cyclooxygenase-1 
Cyclooxygenase-1 is an enzyme that 
speeds up the creation of chemical 
messengers known as prostaglandins in 
several parts of the body, including the 
stomach, kidneys, and inflammatory sites. 
Prostaglandins encourage the formation of 
a protective natural mucus lining in the 
stomach. They also interact within specific 
cells that control inflammation and other 
processes. The activity of cyclooxygenase 
has long been examined in ram seminal 
vesicles, and a homogenous, enzymatically 
active COX was isolated in 1976. (24) 
COX-1 is expressed ubiquitously in most 
tissues and serves as a "housekeeper" by 
synthesizing prostaglandins that regulate 
normal cell activity (in the given figure 3). 
The enzyme's concentration is largely 
steady, however minor increases in 
expression of two to fourfold can occur in 
response to hormone or growth factor 
stimulation. (25) 
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Figure 3. Relationship between the pathways leading to the generation of prostaglandins by 
COX-1 and COX-2. 
Cyclooxygenase-2 
COX-2 protein levels rise along with 
the overproduction of prostaglandins in 
numerous cells and tissues during chronic 
inflammation. The COX-2 gene is part of a 
group of main response genes that includes 
the inducible nitric oxide synthase gene, 
which is triggered during inflammation 
and cell proliferation. (26) Cox-2 catalyzes 
the conversion of arachidonic acid to 
prostaglandins and is an inducible type of 
cyclo-oxygenase. TNF and EGF can 
activate Cox-2, which is produced by 
inflammatory cells like macrophages. 
Cyclooxygenase-2 Selective Inhibition 
NSAIDs differ in the severity of their 
adverse effects at anti-inflammatory doses, 
although having equivalent degrees of 
anti-inflammatory efficacy in the clinic. 
When only one COX was known, this was 
impossible to explain. The discrepancies in 
anti-inflammatory activity of aspirin and 
salicylate, as well as the mechanism of 
action of acetaminophen, were other 
aspects that remained unsolved until the 
discovery of COX-2 (paracetamol). 
In certain cell lines, salicylate has only 
about half the effectiveness of aspirin in 
suppressing COX-2. This profile is 
consistent with salicylate's lack of stomach 
irritation (27) and its lack of platelet 
activity (COX-1). (28) Salicylate appears 
to be active exclusively in whole cells, 
therefore the reduction of COX activity 
could be attributable to a metabolite. 
Acetaminophen is an antipyretic and 
analgesic drug with limited anti-
inflammatory properties. Furthermore, it 
shows only sporadic efficacy against most 
COX preparations, but is much more 
effective at reducing prostaglandin 
synthesis in the brain. (29) Perhaps the 
brain enzyme is a third isoform of 
cyclooxygenase, COX-3, for which no 
specific inhibitors have been discovered. 
COX-1 and COX-2 have different 
functions. 
GI Tract (Gastrointestinal Tract) 
Endogenously generated prostacyclin 
and prostaglandin E2 (PGE2), which 
inhibit gastric acid output and exert a 
direct vasodilator action on the arteries of 
the gastric mucosa, are primarily 
responsible for prostaglandins' 
"cytoprotective" function in preventing 
stomach erosions and ulceration. 
COX-I produces protective prostaglandins 
in most species, including humans, while 
(30) discovered modest amounts of COX-2 
in the normal rat stomach. COX-2 is 
expressed in Helicobacter pylori-infected 
human stomach mucosa and ulcerative 
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colitis. (31) In mice and rats, COX-2 is 
also expressed in the periphery of stomach 
ulcers. 
Kidney 
Vasodilator prostaglandins are required 
for the maintenance of kidney function in 
both animal models of disease and 
individuals with congestive heart failure, 
liver cirrhosis, or renal insufficiency. 
When prostaglandin synthesis is lowered 
by NSAIDs, these patients are at risk of 
renal ischemia. PGE2 and prostacyclin are 
mostly synthesized by COX-I, albeit low 
quantities of COX-2 mRNA have been 
detected. (32) Following salt shortage, 
COX-2 expression in the macula densa is 
also upregulated. The renin-angiotensin 
system may be driven by COX-2 
expression. 
The Central Nervous System (CNS) 
COX-l is located in neurons throughout 
the brain, but it is most numerous in the 
forebrain, where prostaglandins are 
thought to play a role in complex 
integrative activities like autonomic 
nervous system control and sensory 
processing. Pyogenic chemicals like LPS, 
interleukin I (IL-I), or tumor necrosis 
factor (TNF) activate COX-2 mRNA in 
brain tissue and cultured glial cells. (33) 
However, without prior stimulation by 
pro-inflammatory stimuli, low quantities 
of COX-2 protein and COX-2 mRNA have 
been found in forebrain neurons. COX-2 
mRNA is also found in the spinal cord of 
normal rats, suggesting that it is involved 
in the processing of nociceptive stimuli. 
(34) 
System of Reproduction 
In fetal hearts, kidneys, lungs, and 
brains, as well as the decidual lining of the 
uterus, COX-1 expression is substantially 
higher than COX-2 expression. (35, 36) 
COX-I-produced prostaglandins appear to 
be critical for fetuses' survival during 
parturition, as the majority of children 
born to homozygous COX-l knockout 
mice do not survive. (37) COX-2 induction 
is involved in ovulation and is a definite 
trigger for parturition (38), resulting in 
PGF2a release and uterine smooth muscle 
contractions. 
Endothelium 
Prostacyclin is an anti-aggregatory and 
vasodilator produced by endothelial cells. 
They certainly contain COX-I, but (39), 
employing the particular COX-2 inhibitor 
celecoxib, reported that celecoxib 
significantly reduced urine excretion of the 
prostacyclin metabolite at doses up to 800 
mg in volunteers. They came to the 
conclusion that COX-2 is increased in 
circulating endothelial cells, most likely as 
a result of laminar shear stress. (40) 
Ratios of COX-2 to COX-1 
The differences in pharmacology of the 
two enzymes underline the significance of 
discovering the inducible COX-2. (41) 
COX-2 inhibitors such as aspirin, 
indomethacin, and ibuprofen are 
substantially less effective than COX-1 
inhibitors. (42) Indeed, the NSAIDs that 
cause the most stomach damage are those 
that inhibit COX-I the most, such as 
aspirin, indomethacin, and piroxicam. (43) 
Because NSAIDs suppress COX-2, they 
are used to treat inflammation. The 
differences in the adverse effects of 
NSAIDs at their anti-inflammatory levels 
are explained by the range of actions of 
NSAIDs against COX-I compared to 
COX-2. Anti-inflammatory drugs with a 
high potency against COX-2 and a low 
COX-2/COX-l activity ratio have 
substantial anti-inflammatory activity with 
little stomach and kidney adverse effects. 
In anti-inflammatory doses, piroxicam and 
indomethacin showed substantial 
gastrointestinal toxicity. These 
medications are substantially more 
effective against COX-l than COX-2. (44) 
5. Selective COX-2 Inhibitors' Potential 
Therapeutic Applications 
Premature Birth 
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During labor, prostaglandins cause 
uterine contractions. NSAIDs, such as 
indomethacin, postpone premature labor 
by reducing prostaglandin production, but 
they also cause the ductus arteriosus to 
close early and limit urine output by the 
fetal kidneys (Sawdy et al. 1997). Because 
mRNA for COX-2 increases dramatically 
in the amnion and placenta shortly before 
and after the commencement of labor 
(Gibb and Sun, 1996), the delay in the 
delivery process is most likely due to 
inhibition of COX-2, whereas the side 
effects on the fetus are attributable to 
inhibition of COX-1. 
Colon Cancer 
Epidemiological studies have found a 
substantial association between aspirin 
consumption and a lower risk of colon 
cancer. (45, 46) Sulindac also reduced 
prostaglandin synthesis and adenomatous 
polyp regression in 11 of 15 patients with 
familial adenomatous polyposis (FAP), a 
syndrome in which many colorectal polyps 
form spontaneously and proceed to 
malignancies. COX-2 (but not COX-I) is 
significantly expressed in human and 
animal colon cancer cells, as well as in 
human colorectal adenocarcinomas, 
indicating that COX activity is involved in 
the process leading to colon cancer. (47, 
48) 
Alzheimer's disease is a type of dementia 
that affects people. 
Because there is no animal model of 
Alzheimer's disease, the link between 
COX and the disease has been established 
primarily in epidemiology. A number of 
studies have found that those who take 
NSAIDs as anti-inflammatory medication 
had a lower risk of Alzheimer's disease. 
(49-51). It's likely that the aspirin dose was 
too low to have an anti-inflammatory 
impact. The protective effect of NSAIDs is 
in line with findings of inflammatory 
activity in Alzheimer's disease 
pathogenesis. COX-2 has a lot of interest 
in Alzheimer's disease, and (52) found 
COX-2 expression in the frontal cortex of 
Alzheimer's patients' brains. 
6. Conclusions 
Industrial screening programs 
discovered selective COX-2 inhibitors as 
strong NSAIDs with low toxicity in the 
stomach and kidneys even before the 
COX-2 enzyme was identified, employing 
models of chronic inflammation in 
conjunction with models of gastric injury. 
The evidence that selective COX-2 
inhibitors will have considerably 
decreased side effects is strong, both in 
animal experiments and in clinics. Anti-
inflammatory therapy will benefit greatly 
from selective COX2 inhibitors. They are 
unlikely to be more effective anti-
inflammatory medicines than traditional 
NSAIDs, but they will have the significant 
benefit of being safer and more well 
tolerated. Meloxicam's clinical findings 
already suggest that it has enhanced safety 
and tolerability, despite the fact that it still 
has some COX-I action. In the future, 
these medications may be used to prevent 
colon cancer, Alzheimer's disease, and 
premature labor, in addition to their 
positive effects in inflammatory illnesses. 
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